Telomerase Reverse Transcriptase: Difference between revisions
Eran Hodis (talk | contribs) |
David Canner (talk | contribs) No edit summary |
||
| Line 66: | Line 66: | ||
Development of cancer chemotherapeutics directed against the reverse-transcriptase domain of telomerase has been challenging, perhaps because the enzyme needs only low activity to maintain telomeres. | Development of cancer chemotherapeutics directed against the reverse-transcriptase domain of telomerase has been challenging, perhaps because the enzyme needs only low activity to maintain telomeres. | ||
Because the TEN domain is essential for telomerase activity and its structure seems to be conserved trough evolution, this portion of TERT is a potential new target for antitelomerase compounds. | Because the TEN domain is essential for telomerase activity and its structure seems to be conserved trough evolution, this portion of TERT is a potential new target for antitelomerase compounds. | ||
==Additional Resources== | |||
For additional information, See: [[Cancer]] | |||
<br /> | |||
== '''References''' == | == '''References''' == | ||